Correspondence


M BLOTT and A GREENOUGH
Department of Child Health,
Frederic Still Neonatal Intensive Care Unit,
King’s College School of Medicine and Dentistry,
London SE5 9PJ

Marfan’s syndrome in mitral valve disease

Sir,

We read with interest the report by Marlow et al on an infant with Marfan’s syndrome and mitral valve dysfunction who died after acute illness with gross cardiac failure.1 The authors stated that ‘disease affecting the mitral valve is usually more benign than that of the aortic valve . . .’. This statement, however, may not be applicable to infants and young children with Marfan’s syndrome. We have recently reported on the clinical course and the echocardiographic findings in 25 children with this syndrome.2 Prolapse of the mitral valve leaflets was shown by echocardiography in all the patients and aortic pathology in 80% of the cases. Five patients died during the follow up period (mean 5±4.5 years); two of them were infants with severe mitral insufficiency and progressive congestive heart failure. The other three patients died during the second decade of life from complications of the aortic pathology. Another series reported by Sisk et al showed that among 15 patients with Marfan’s syndrome diagnosed before 4 years of age, mitral valve dysfunction was the leading cause of cardiovascular morbidity and mortality.3 These data indicate that mitral valve disease is the most common cause of congestive heart failure and death in infants and young children with Marfan’s syndrome.

References


T GEVA and M FRAND
Department of Pediatrics C,
The Chaim Sheba Medical Center,
Tel Hashomer 52621
and Sackler School of Medicine,
Tel Aviv University,
Israel

Medical staffing in paediatric departments in district general hospitals

Sir,

Dr Nelson is right.1 At this hospital we have only two senior house officers, often with no previous paediatric experience, on a 1:2 rota, without any intermediate cover, to cover general and neonatal wards including labour ward resuscitation. We do not therefore have a 1:3 rota, nor a ‘safety net’. Five years of local discussions have not altered this. What is needed is a united and forceful voice from the British Paediatric Association nationally, coupled with specific advice for consultant paediatricians on how to get past the embargos on increasing junior staff.

Reference


F N PORTER and C S NANAYAKARA
Grantham and Kesteven General Hospital,
Grantham, Lincolnshire NG31 8DG

Maternal narcotic abuse and the newborn

Sir,

We were interested in the report by AlRoomi et al concerning maternal narcotic abuse and its effects on newborn infants.1 Women on Merseyside smoke heroin rather than inject it and we would like to report aspects of our experience of 37 infants born to women who inhaled heroin.

(1) AlRoomi et al used phenobarbitone and chloral as first line drugs for the treatment of symptoms, but they make no comment on the effectiveness of these agents. In our series 15 (40%) babies also developed withdrawal signs but our initial experience with phenobarbitone by injection was disappointing. We subsequently tried oral chlorpromazine, which we stopped using because of its epileptogenic potential, although it was effective. We now consider that treatment with pure aqueous morphine sulphate (0.125 mg) given orally and as required is pharmacologically appropriate, have found it effective, and would recommend its use.

(2) In our series only eight (22%) children were subject to legal constraints, compared with 38% in AlRoomi’s series. While this may simply reflect a different approach to social management, it may be that heroin abuse by inhalation has less disruptive effects on family life.

(3) We also found that these children were not brought to hospital for follow up appointments. We now consider that community based surveillance is more appropriate.

Reference


J E M GREGG, D C DAVIDSON, and A M WEINDLING
Fazakerley Hospital,
Liverpool L9 7AL